U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C20H26N2O2
Molecular Weight 326.4326
Optical Activity ( + )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EPSIPRANTEL, (+)-

SMILES

O=C(C1CCCCC1)N2CC3N(CCCC4=C3C=CC=C4)C(=O)C2

InChI

InChIKey=LGUDKOQUWIHXOV-UHFFFAOYSA-N
InChI=1S/C20H26N2O2/c23-19-14-21(20(24)16-8-2-1-3-9-16)13-18-17-11-5-4-7-15(17)10-6-12-22(18)19/h4-5,7,11,16,18H,1-3,6,8-10,12-14H2

HIDE SMILES / InChI

Molecular Formula C20H26N2O2
Molecular Weight 326.4326
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Epsiprantel is a veterinary drug which is used as an antiparasitic agent. Epsiprantel in tablets (Cestex) is indicated for the removal of tapeworms in the cat (Dipylidium caninumand Taenia taeniaeformis) and dog (Dipylidium caninum and Taenia pisiformis). Epsiprantel acts directly on the tapeworm. Since it is minimally absorbed following oral administration, epsiprantel remains at the site of action within the gastrointestinal tract. Due to digestive process, tapeworm fragments or proglottids may not be readily visible in the stool. Epsiprantel is not a cholinesterase inhibitor. During the course of clinical field studies, Cestex was administered concurrently with diethylcarbamazine citrate (dogs only), anti-inflammatory agents, insecticides, and nematocides with no drug incompatibilities noted. The mechanism of action of epsiprantel appears to be similar to that of praziquantel, a drug that disrupts the regulation of calcium and other cations. Tetanic muscle contraction and paralysis occurs in the parasite, and the tegument becomes vacuolized

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CESTEX

Approved Use

Unknown

Launch Date

1989
PubMed

PubMed

TitleDatePubMed
Synthesis and anthelmintic activity of a series of pyrazino[2,1-a][2]benzazepine derivatives.
1989 Sep
Patents

Patents

Sample Use Guides

veterinary use: cats: 1.25 mg/lb of body weight dogs: 2.5 mg/lb of body weight
Route of Administration: Oral
In Vitro Use Guide
epsiprantel at a concentration of 10 ug ml-1 caused tegumental damage and death of protoscoleces, juveniles (seven-day-old) and adult (37-day-old) Echinococcus granulosus.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:36:11 GMT 2023
Edited
by admin
on Sat Dec 16 09:36:11 GMT 2023
Record UNII
WUC74DW9SN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EPSIPRANTEL, (+)-
Common Name English
PYRAZINO(2,1-A)(2)BENZAZEPIN-4(1H)-ONE, 2-(CYCLOHEXYLCARBONYL)-2,3,6,7,8,12B-HEXAHYDRO-, (+)-
Systematic Name English
(+)-2-(CYCLOHEXYLCARBONYL)-2,3,6,7,8,12B-HEXAHYDROPYRAZINO(2,1-A)(2)BENZAZEPIN-4(1H)-ONE
Common Name English
Code System Code Type Description
FDA UNII
WUC74DW9SN
Created by admin on Sat Dec 16 09:36:11 GMT 2023 , Edited by admin on Sat Dec 16 09:36:11 GMT 2023
PRIMARY
PUBCHEM
72026
Created by admin on Sat Dec 16 09:36:11 GMT 2023 , Edited by admin on Sat Dec 16 09:36:11 GMT 2023
PRIMARY
CAS
98123-66-1
Created by admin on Sat Dec 16 09:36:11 GMT 2023 , Edited by admin on Sat Dec 16 09:36:11 GMT 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> ENANTIOMER
RACEMATE -> ENANTIOMER